Ezetimibe: Cholesterol lowering and beyond

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 4, 2008, Pages 447-470

  Bays, Harold E ^a   Neff, David ^b   Tomassini, Joanne E ^b   Tershakovec, Andrew M ^b  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Ezetimibe; HDL C; Non HDL C; Oxysterols; Phytosterols; RLP C

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ABC TRANSPORTER; ACETYL COENZYME A; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; CHYLOMICRON REMNANT; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; OXYSTEROL; PHYTOSTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; AZETIDINE DERIVATIVE; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

ADD ON THERAPY; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INTESTINE ABSORPTION; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG COMBINATION; METABOLISM; REVIEW;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL; CONTROLLED CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA;

EID: 43049183509     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.4.447     Document Type: Article

References (137)

1. Grundy SM, Cleeman JI, Metz CN et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 110(2), 227-239 (2004).
2. Bays H, McKenney J, Davidson M. Torcetrapib/atorvastatin combination therapy. Expert Rev. Cardiovasc. Ther. 3(5), 789-820 (2005).
3. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360(9326), 7-22 (2002).
4. Robinson JG, Smith B, Maheshwari, N, Schrott H. Pleiotropic effects of statins beyond cholesterol reduction? J. Am. Coll. Cardiol. 46 (10), 1855-1862 (2005).
5. Bays H. Ezetimibe. Expert Opin. Investig. Drugs 11(11), 1587-1604 (2002).
6. Robinson JG, Davidson MH. Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Rev. Cardiovasc. Ther. 4(4), 461-476 (2006).
7. Burnett JR, Huff MW. Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia. Expert Opin. Investig. Drugs 15(11), 1337-1351 (2006).
8. Santosa S, Varady KA, AbuMweis S, Jones PJ. Physiological and therapeutic factors affecting cholesterol metabolism: does a reciprocal relationship between cholesterol absorption and synthesis really exist? Life Sci. 80(6), 505-514 (2007).
9. Turley SD, Dietschy JM. Sterol absorption by the small intestine. Curr. Opin. Lipidol. 14(3), 233-240 (2003).
10. Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin. Pharmacother. 4(5), 779-790 (2003).
11. Mayes PA. Cholesterol synthesis, transport and excretion. In: Harper's Biochemistry (25th Edition). Murray RK, Granner DK, Mayes PA, Rodwell VW (Eds). Appleton & Lange, CT, USA, 285-305 (2000).
12. Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J. Lipid. Res. 34(10), 1637-1659 (1993).
13. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res. 96(12), 1221-1232 (2005).
14. Ikonen E. Mechanisms for cellular cholesterol transport: defects and human disease. Physiol. Rev. 86(4), 1237-1261 (2006).
15. Gylling H. Cholesterol metabolism and its implications for therapeutic interventions in patients with hypercholesterolaemia. Int. J. Clin. Pract. 58(9), 859-866 (2004).
16. Kruit JK, Groen AK, van Berkel TJ, Kuipers F. Emerging roles of the intestine in control of cholesterol metabolism. World J. Gastroenterol. 12(40), 6429-6439 (2006).
17. Lee MH, Lu K, Hazard S et al. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat. Genet. 27(1), 79-83 (2001).
18. Wang, Q-H. Regulation of intestinal cholesterol absorption. Annu. Rev. Physiol. 69, 221-48 (2007).
19. Berge KE, Tian H, Graf GA et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 290(5497), 1771-1775 (2000).
20. Stanek EJ, Sarawate C, Willey VJ, Charland SL, Cziraky MJ. Risk of cardiovascular events in patients at optimal values for combined lipid parameters. Curr. Med. Res. Opin. 23(3), 553-563 (2007).
21. Salen G, von Bergmann K, Lutjohann D et al. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 109(8), 966-971 (2004).
22. Yu LQ, Li-Hawkins J, Hammer RE et al. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J. Clin. Invest. 110(5), 671-680 (2002).
23. Kruit JK, Plosch T, Havinga R et al. Increased fecal neutral sterol loss upon liver X receptor activation is independent of biliary sterol secretion in mice. Gastroenterology 128(1), 147-156 (2005).
24. Brunham LR, Kruit JK, Iqbal J et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J. Clin. Invest. 116(4), 1052-1062 (2006).
25. Wu AL, Windmueller HG. Relative contributions by liver and intestine to individual plasma apolipoproteins in the rat. J. Biol. Chem. 254(45), 7316-7322 (1979).
26. Davis HR, Zhu LJ, Hoos LM et al. Niemann-Pick C1 like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J. Biol. Chem. 279(32), 33586-33592 (2004).
27. Garcia-Calvo M, Lisnock JM, Bull HG et al. The target of ezetimibe is Niemann-Pick Cl-Like 1 (NPC1L1). Proc. Natl. Acad. Sci. USA 102(23), 8132-8137 (2005).
28. Lammert F, Wang DQ. New insights into the genetic regulation of intestinal cholesterol absorption. Gastroenterology 129(2), 718-734 (2005).
29. Catapano AL. The pharmacologic elegance of inhibiting cholesterol absorption and synthesis while providing a homeostatic balance. Fundam. Clin. Pharmacol. 21 (2), 21-26, (2007).
30. Ternel RE, Tang W, Ma Y et al. Hepatic Niemann-Pirk C1-like 1 regulate biliary concentration and is a target of ezetimibe. J. Clin. Invest. 117 (7), 1968-1978 (2007).
31. van Heek M, Compton DS, Davis HR. The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. Eur. J. Pharmacol. 415(1), 79-84 (2001).
32. Bays H, Stein EA. Pharmacotherapy for dyslipidaemia - current therapies and future agents. Expert Opin. Pharmacother. 4(11), 1901-1938 (2003).
33. Davis HR, Compton DS, Hoos LM, Tetzloff GG. Ezetimibe reduces plasma cholesterol and inhibits the development of atherosclerosis in apo E knockout mice with and without LDL receptors. Circulation 102(18), 186 (2000).
34. Repa JJ, Turley SD, Quan G, Dietschy JM. Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption. J. Lipid. Res. 46(4), 779-789 (2005).
35. Tremblay AJ, Lamarche B, Cohn JS, Hogue JC, Couture P. Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 26(5), 1101-1106 (2006).
36. Hachem SB, Mooradian AD. Familial dyslipidaemias: an overview of genetics, pathophysiology and management. Drugs 66(15), 1949-1969 (2006).
37. Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 105(21), 2469-2475 (2002).
38. Baigent C, Keech A, Kearny PM et al.; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267-1278 (2005).
39. Lamon-Fava S, Diffenderfer MR, Barrett PH et al. Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism. J. Lipid Res. 48(8), 1746-1753 (2007).
40. Holdgate GA, Ward WHJ, McTaggart F. Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochem. Soc. Trans. 31(Pt 3), 528-531 (2003).
41. Toth PP, Davidson MH. Cholesterol absorption blockade with ezetimibe. Curr. Drug Targets Caradiovasc. Haematol. Disord. 5(6), 455-462 (2005).
42. Miettinen TA, Gylling H. Ineffective decrease of serum cholesterol by simvastatin in a subgroup of hypercholesterolemic coronary patients. Atherosclerosis 164(1), 147-152 (2002).
43. Miettinen TA, Gylling H. Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment. Eur. J. Clin. Invest. 33(11), 976-982 (2003).
44. Altmann SW, Davis HR, Zhu LJ et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 303(5661), 1201-1204 (2004).
45. Vasudevan AR, Jones PH. Effective use of combination lipid therapy. Curr. Atheroscler. Rep. 8(1), 76-84 (2006).
46. Telford DE, Sutherland BG, Edwards JY, Andrews JD, Barrett PH, Huff MW. The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin. J. Lipid. Res. 48(3), 699-708 (2007).
47. Sudhop T, Lutjohann D, Kodal A et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 106(15), 1943-1948 (2002).
48. Bays HE, Moore PB, Drehobl MA et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two Phase II studies. Clin. Ther. 23(8), 1209-1230 (2001).
49. Dujovne CA, Ettinger MP, McNeer JF et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am. J. Cardiol. 90(10), 1092-1097 (2002).
50. Knopp RH, Gitter H, Truitt T et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur. Heart J. 24(8), 729-741 (2003).
51. Stein E. Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor. Eur. Heart J. 3(Suppl. E), E11-E16 (2001).
52. Mandema JW, Hermann D, Wang W et al. Model-based development of gemcabene, a new lipid-altering agent. AAPS J. 7(3), E513-E522 (2005).
53. Zetia. Product insert. 2001.
54. Gagne C, Bays HE, Weiss SR et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am. J. Cardiol. 90(10), 1084-1091 (2002).
55. Pearson TA, Denke MA, McBride PE, Battisti WP, Brady VVE, Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin. Proc. 80(5), 587-595 (2005).
56. Masana L, Mara P, Gagne C et al. Longterm safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. Clin. Ther. 27(2), 174-184 (2005).
57. Davidson MH, Ballantyne CM, Kerzner B et al. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int. J. Clin. Pract. 58(8), 746-755 (2004).
58. Davidson MH, McGarry T, Bettis R et al. Ezetimibe coadministered with simvastatin in patients with primary' hypercholesterolemia. J. Am. Coll Cardiol. 40(12), 2125-2134 (2002).
59. Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin. Proc. 79(5), 620-629 (2004).
60. Feldman T, Koren M, Insull WJ Jr et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am. J. Cardiol. 93(12), 1481-1486 (2004).
61. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am. J. Cardiol. 93(12), 1487-1494 (2004).
62. Sager PT, Melani L, Lipka L et al. for the Ezetimibe Study Group. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am. J. Cardiol. 92(12), 1414-1418 (2003).
63. Sager PT, Capece R, Lipka L et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis 179(2), 361-367 (2005).
64. Ballantyne CM, Houri J, Notarbartolo A et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 107(19), 2409-2415 (2003).
65. Bays HE, Ose L, Fraser N et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin. Ther. 26(11), 1758-1773 (2004).
66. Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am. Heart J. 149(3), 464-473 (2005).
67. Catapano AL, Davidson MH, Ballantyne CM et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr. Med. Res. Opin. 22(10), 2041-2053 (2006).
68. Simons L, Tonkon M, Masana L et al. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Curr. Med. Res. Opin. 20(9), 1437-1445 (2004).
69. Denke M, Pearson T, McBride P, Gazzara RA, Brady WE, Tershakovec AM. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diab. Vasc. Dis. Res. 3(2), 93-102 (2006).
70. Goldberg RB, Guyton JR, Mazzone T et al. Ezetimibe/Simvastatin vs atorvastatin in patients with Type 2 diabetes mellitus and hypercholesterolemia: The VYTAL study. Mayo Clin. Proc. 81(12), 1579-1588 (2006).
71. Smith SC, Jr, Allen J, Blair SN et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113(19), 2363-2372 (2006).
72. Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 106(20), 2526-2529 (2002).
73. Chapman MJ and Caslake M. Non-high-density lipoprotein cholesterol as a risk factor: addressing risk associated with apolipoprotein B-containing lipoproteins. Eur. Heart J. Supplements 6, A43-A48 (2004).
74. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106(25), 3143-3421 (2002).
75. Robinson JG, Davidson MH, Shah A et al. Efficacy and safety of ezetimibe and czetimibe plus statin therapy in patients aged under 65, 65-74 and 75 years and older Aging Health 3(6) 691-705 (2007).
76. American Diabetes Association. Standards of medical care in diabetes - 2006. Diabetes Care 29(Suppl. 1), S4-S42 (2006).
77. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Executive Summary. Circulation 112(17), e285-e290 (2005).
78. Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ. Action of atorvastatin in combined hyperlipidemia - preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler. Thromb. Vasc. Bio. 20(1), 189-197 (2000).
79. Schaefer EJ, Asztalos BF. The effects of statins on high-density lipoproteins. Curr. Atheroscler. Rep. 8(1), 41-49 (2006).
80. Timmins JM, Lee JY, Boudyguina E et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J. Clin. Invest. 115(5), 1333-1342 (2005).
81. Chung BH, Liang P, Doran S, Cho BH, Franklin F. Postprandial chylomicrons: potent vehicles for transporting cholesterol from endogenous LDL+HDL and cell membranes to the liver via LCAT and CETP. J. Lipid Res. 45(7), 1242-1255 (2004).
82. Taggart W, Lutjohann D, Musliner T, Sudhop T, Shah A, von Bergmann K. Inhibition of intestinal cholesterol absorption and endogenous cholesterol production by ezetimibe/simvastatin in man. J. Clin. Lipid 1(5), 437 (2007).
83. Briand F, Millar J, Billheimer J, Rothblat G, Rader D. Inhibition of cholesterol absorption with ezetimibe promotes macrophage to feces reverse cholesterol transport in mice. Circulation 116, II159-II160 (2007).
84. Pedersen TR, Faergeman O, Kastelein JJP et al. for the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction. The IDEAL Study: a randomized controlled trial. JAMA 294, 2437-2445 (2005).
85. Waters DD, Guyton JR, Herrington DM, McGowan MP, Wenger NK, Shear C; TNT Steering Committee Members and Investigators Treating to New Targets (TNT) Study. Does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am. J. Cardiol. 93, 154-158 (2004).
86. Barter PJ, Ballantyne CM, Carmena R et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy. report of the thirty-person/ten-country panel. J. Intern. Med. 259(3), 247-258 (2006).
87. Sniderman AD. Apolipoprotein B versus non-high-density lipoprotein cholesterol: and the winner is... Circulation 112(22), 3366-3367 (2005).
88. Stein EA, Sniderman A, Laskarzewski P. Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B. Am. J. Cardiol. 96(9A), 36K-43K (2005).
89. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampler MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 112(22), 3375-3383 (2005).
90. Genest J, Frohlich J, Fodor G, McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CAM J 169(9), 921-924 (2003).
91. Denke MA. Weighing in before the fight: low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol versus apolipoprotein B as the best predictor for coronary heart disease and the best measure of therapy. Circulation 112(22), 3368-3370 (2005).
92. Basso F, Freeman LA, Ko C et al. Hepatic ABCG5/G8 overexpression reduces apoB-lipoproteins and atherosclerosis when cholesterol absorption is inhibited. J. Lipid Res. 48(1), 114-126 (2007).
93. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl J. Med. 347(20), 1557-1565 (2002).
94. Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107(3), 499-511 (2003).
95. Nissen SE, Tuzcu EM, Schoenhagen P et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med. 352(1), 29-38 (2005).
96. Ridker PM, Cannon CP. Morrow D et al. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 352(1), 20-28 (2005).
97. Pearson T, Ballantyne CM, Sisk C, Shah A, Veltri ER, Maccubbin D. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am. J. Cardiol. 99(12), 1706-1713 (2007).
98. Pearson T, Ballantyne CM, Veltri ER et al. CRP and D LDL-C response to ezetimibe: monothcrapy and add-on to baseline statin. Triennial international symposium on drugs affecting lipid metabolism. J. Clin. Lipidol. 1(5), 466 (2007).
99. Malik S, Wong ND, Franklin S, Pio J, Fairchild C, Chen R. Cardiovascular disease in US patients with metabolic syndrome, diabetes, and elevated C-rcactive protein. Diabetes Care 28(3), 690-693 (2005).
100. Ray KK, Cannon CP, Cairns R et al. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 Trial. J. Am. Coll Cardiol. 46(8), 1417-1424 (2005).
101. Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein - a meta-analysis. J. Am. Coll. Cardiol. 49(20), 2003-2009 (2007).
102. Arnaud C, Burger F, Steffens S et al. Statins reduce interleukin-6-induced C-rcactive protein in human hepatocytes - new evidence for direct antinflammatory effects of statins. Arterioscler. Thromb. Vasc. Bio. 25(6), 1231-1236 (2005).
103. Seedorf U, Engel T, Lueken A, Bode G, Lorkowski S, Assmann G. Cholesterol absorption inhibitor Ezetimibe blocks uptake of oxidized LDL in human macrophages. Biochem. Biophys. Res. Comm. 320(4), 1337-1341 (2004).
104. Orso E, Werner T, Wolf Z, Bandulik S, Kramer W, Schmitz G. Ezetimibe influences the expression of raft-associated antigens in human monocytes. Cytometry A 69(3), 206-208 (2006).
105. McNamara JR, Shah PK, Nakajima K et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis 154(1), 229-236 (2001).
106. Karpe F, Boquist S, Tang R, Bond GM, de Faire U, Hamsten A. Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides. J. Lipid Res. 42 (1), 17-21 (2001).
107. Imke C, Rodriguez BL, Grove JS et al. Are remnant-like particles independent predictors of coronary heart disease incidence? The Honolulu Heart study. Arterioscler Thromb. Vasc. Biol. 25(8), 1718-1722 (2005).
108. Twicker TB, Dallinga-Thie GM, Cohn JS, Chapman MJ. Elevated remnant-like particle cholesterol concentration - a characteristic feature of the atherogenic lipoprotein phenotype. Circulation 109(16), 1918-1925 (2004).
109. Cohn JS, Marcoux C, Davignon J. Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins. Arteriosler. Thromb. Vasc. Biol. 19(10), 2474-2486 (1999).
110. Harchaoui KE, van der steeg WA, Stores ES. Value of Low-density lipoprotein particle number and size as predictor of coronary artery disease in apparently healthy men and women. The EPIC-Norfolk Prospective population study. J. Am. Coll. Cardiol. 49, 547-553 (2007).
111. Packard CJ, Ford I, Robertson M et al. Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 112(20), 3058-3065 (2005).
112. St Pierre AC, Cantin B, Dagenais GR et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler. Thromb. Vasc. Biol. 25(3), 553-559 (2005).
113. Rosenson RS, Orvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am. J. Cardiol. 90(2), 89-94 (2002).
114. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 82(2), 495-506 (1990).
115. Farnier M, Freeman MW, Macdonell G et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur. Heart J. 26(9), 897-905 (2005).
116. Tribble D, Farnier M, Freeman MW et al. Effect of fenofibrate and ezetimibe on lipoprotein subclasses and LDL subclass pattern in patients with mixed hyperlipidemia. Circulation 110(17, Suppl.), III143-III144 (2004).
117. Ose L, Olegario KQ, Reyes R, Johnson-Levonas AO, Sapre A, Tribble D. Effects of ezetimibe/simvastatin on lipoprotein subclasses in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques. Clin. Ther. 29 (11), 2419-2432 (2007).
118. Kalogirou M, Tsimihodimos V, Gazi I et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr. Med. Res. Opin. 23(5), 1169-1176 (2007).
119. Kolovou GD, Anagnostopoulou KK, Salpea KD, Daskalopoulou SS, Mikhailidis DP. The effect of statins on postprandial lipemia. Curr. Drug Targets 8(4), 551-560 (2007).
120. Chan YM, Varady KA, Lin Y et al. Plasma concentrations of plant sterols: physiology and relationship with coronary heart disease. Nutr. Rev. 64(9), 385-402 (2006).
121. Normen L, Shaw CA, Fink CS, Awad AB. Combination of phytosterols and omega-3 fatty acids: a potential strategy to promote cardiovascular hcalth. Curr. Med. Chem. Cardiovasc. Hematol. Agents 2(1), 1-12 (2004).
122. Matthan N, Larocque JM, Pencina M et al. Increased cholesterol absorption and decreased cholesterol synthesis characterize Framingham Offspring Study participants with coronary heart disease. Circulation 112(17 Suppl. S), U892-U893 (2005).
123. Fassbender K, Lutjohann D, Dik MG et al. Moderately elevated plant sterol levels are associated with reduced cardiovascular risk-The LASA study. Atherosclerosis (doi:10.1016/j.atherosclerosis.2006.10. 032) (2006).
124. Pinedo S, Vissers MN, von Bergmann K et al. Plasma levels of plant sterols and the risk of coronary artery disease: the prospective EPIC-Norfolk Population Study. J. Lipid Res. 48 (1), 139-144 (2007).
125. Thiery J, Ceglarek U, Fiedler G et al. Elevated campesterol serum levels - a significant predictor of incident myocardial infarction: Results of the population-based MONICA/KORA follow-up study 1994 to 2005. Circulation 114(18 Suppl. S), 884 (2006).
126. Wilund KR, Yu L, Xu F et al. No association between plasma levels of plant sterols and atherosclerosis in mice and men. Arterioscler. Thromb. Vasc. Biol. 24(12), 2326-2332 (2004).
127. John S, Sorokin AV, Thompson PD. Phytosterols and vascular diseases. Curr. Opin. Lipidol. 18 (1), 35-45 (2007).
128. Sudhop T, Lutjohann D, Reber D et al. Inhibition of intestinal cholesterol absorption and endogenous cholesterol synthesis by ezetimibe/ simvastatin in humans. J. Am. Coll. Cardiol 45(3 Suppl A), 392A (2005).
129. Assmann G, Kannenberg F, Musliner T, Ramey D, Veltri ER. Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia. Curr. Med. Res. Opin. 24(1), 249-259 (2008).
130. Schroepfer GJ Jr. Oxysterols: modulators of cholesterol metabolism and other processes. Physiol. Rev. 80(1), 361-554 (2000).
131. Staprans I, Pan XM, Rapp JH, Grunfeld C, Feingold KR. Oxidized cholesterol in the diet accelerates the development of atherosclerosis in LDL receptor- and apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 20(3), 708-714 (2000).
132. Staprans I, Pan XM, Rapp JH, Feingold KR. Oxidized cholesterol in the diet is a source of oxidized lipoproteins in human serum. J. Lipid Res. 44(4), 705-715 (2003).
133. Staprans I, Pan XM, Rapp JH, Moser AH, Feingold KR. Ezetimibe inhibits the incorporation of dietary oxidized cholesterol into lipoproteins. J. Lipid Res. 47(11), 2575-2580 (2006).
134. Kastelein JJ, Sager PT, de Groot E, Veltri E. Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. Am. Heart J. 149 (2), 234-239 (2005).
135. Rossebo A, Pedersen T, Allen C et al. Design and baseline characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study. Am. J. Cardiol. 99(7), 970-973 (2007).
136. Baigent C, Landry M. Study of heart and renal protection. Kidney Int. 63 (S84), 207-210 (2003).
137. Cannon CP, Guigliano RP, Blazing MA et al for the IMPROVE-IT investigators. Design and Rationale of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimibe/ simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndrome. Am. Heart J. (2007). [Epub ahead of print].